Cancer treatment is associated with significant morbidity and mortality. Surgery is a mainstay of treatment for many tumours, and anaesthetists care for cancer patients on a daily basis. Surgery itself induces a stress response and inhibits the immune system, and cancer surgery is associated with the release of tumour cells systemically. Preclinical and clinical studies suggest that the anaesthetics and adjuvants given in the perioperative period can affect cancer recurrence and survival, perhaps tipping the balance in some instances to determine whether cancer progresses or regresses. Retrospective studies have hinted that regional anaesthesia can play a protective role in cancer surgery, but many of these studies are small and subject to bias. We eagerly await the results of several large, randomized controlled trials examining the impact of regional anaesthesia and analgesia on cancer recurrence and survival.
• Considerable evidence suggests that anaesthesia can have both direct and indirect effects on cancer cell survival and metastasis.
• Small retrospective clinical trials suggest that regional anaesthesia is associated with improved survival in cancer surgery.
• Large randomized clinical trials comparing the effects of regional and general anaesthesia on long-term outcome after cancer surgery are necessary to guide clinical practice.
Surgery induces a stress response, and both surgery and anaesthetics can impair the immune system. This immunosuppression could provide a window in which tumour cells released during surgical excision could escape immunosurveillance and induce metastasis. Commonly administered anaesthetic agents could also promote cancer growth and spread. There is a growing body of literature suggesting that regional anaesthesia might be protective against these processes ( Fig. 1 ).
Cancer and the immune system
In order to understand how surgery and anaesthesia affect cancer recurrence and survival, one first needs to understand the basics of cancer biology. The tumour microenvironment consists of cancer cells and various inflammatory cells and mediators. Both tumour and inflammatory cells secrete a complex array of chemical and protein signalling molecules that act in both an autocrine and a paracrine manner to influence cancer growth and metastasis. A tumour can be viewed as an organism unto itself, and establishes an intricate physical and chemical relationship with the body and the immune system. Many of the molecular and cellular mechanisms underlying this process remain to be elucidated fully.
It has long been recognized that cancer can occur at sites of inflammation and injury, and it is now known that inflammatory cells and mediators play a key role in cancer formation and progression. Cancer can form in the setting of DNA damage and somatic alterations. These changes have been termed 'initiation' and can persist in cells indefinitely until a second injury or 'promotion' occurs. Promotion can be caused by inflammation, injury, irritants or a host of other exposures. Promotion results in recruitment of inflammatory cells, release of chemical mediators, and oxidative damage, and ultimately, a failure of apoptosis that results in undeterred cellular proliferation. 1 Angiogenesis is required for tumour growth and metastasis formation and is the process by which new vessels form from existing endothelial cells. Angiogenesis normally happens in response to injury and inflammation and is characterized by the degradation and remodelling of the extracellular matrix and the proliferation and migration of endothelial cells. Angiogenesis is critical to the survival of tumours, and thus has been the target of many recent treatments for cancer. 2 The immune system plays a key role in both the progression and the regression of cancer cells. The immune system can be divided into the innate and the adaptive systems. The innate system is made up of epithelial barriers, granulocytes, macrophages, natural killer (NK) cells, and dendritic cells. This system is the first line of defence against invading organisms and tumour cells. The adaptive immune system serves to eliminate threats that have evaded the innate immune system. It comprises humoural immunity, or the antibody-mediated response, and cell-mediated immunity, mediated by T lymphocytes. 3 Activated T cells are categorized by the cytokines that they secrete. The Thelper (Th) 1 cytokines [interferon-γ, tumour necrosis factor-α (TNF -α), and interleukin (IL)-2, IL-12, IL-15, and IL-18] promote inflammation, stimulate B cells, activate macrophages, and promote cytotoxic T-cell development. The Th2 cytokines (IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13) are involved in stimulating IgE production and eosinophil development. 4 Interleukin-1 is yet another pro-inflammatory cytokine, produced mainly by monocytes and macrophages. It is a key regulator of inflammation and immune responses.
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Inflammatory cells are present early in the neoplastic process and play an important role in the tumour microenvironment. These cells include leucocytes (neutrophils, monocytes, eosinophils, and basophils) and lymphocytes (T cells, B cells, and NK cells). Inflammatory cells secrete an array of cytokines and chemokines. Some important cytokines and factors involved in tumour progression include vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs), TNF-α, and transforming growth factor-β (TGF-β). 1 Vascular endothelial growth factor is secreted by tumour cells and by macrophages, fibroblasts, endothelial cells, and stromal cells. Vascular endothelial growth factor is a powerful trigger for angiogenesis, stimulating signalling pathways to induce proliferation and migration of endothelial cells. It also increases vascular permeability and can function as a chemoattractant to recruit regulatory T cells. Tumour cells express tyrosine kinase VEGF receptors, and tumour-secreted VEGF functions in an autocrine manner to cause de-differentiation and tumour spread. 6 Matrix metalloproteinases are a family of endopeptidases with diverse actions in the tumour microenvironment. They are produced by a variety of cell types, including inflammatory cells and stromal cells, such as fibroblasts. Matrix metalloproteinases degrade portions of the extracellular matrix and can result in angiogenesis, although they also generate angiogenesis inhibitors. They have been shown both to promote and to inhibit apoptosis, and to recruit inflammatory cells through release of chemokines. 1 2 Tumour necrosis factor-α is a cytokine involved in systemic inflammation and the regulation of immune cells. It can be produced by many cell types and is important in tumour promotion, regulating a host of cytokines and MMPs that contribute to angiogenesis. Transforming growth factor-β is a cytokine involved in cell growth, differentiation, and other functions. In normal cells it halts proliferation, promotes differentiation, and induces apoptosis. In many types of cancer, portions of the TGF-β signalling pathway malfunction, causing loss of control over cellular proliferation. It can also be a stimulator of angiogenesis in vivo. 1 7 Prostaglandin E 2 (PGE 2 ) is a key mediator of the immune system in both chronic infection and cancer. Prostaglandins are derived from arachidonic acid by cyclooxygenases (COX) 1 and 2 and by prostaglandin synthases. Many cancers have elevated concentrations of COX2 and overproduce prostaglandins. Prostaglandin E 2 is crucial to inflammation and phagocytemediated immunity, and to limiting the potentially harmful activation of cytotoxic cells. 8 Prostaglandin E 2 plays an important role in promoting cancer progression by inhibiting apoptosis, stimulating angiogenesis, and enhancing invasion. Surgery and the stress response
Surgical resection is a mainstay of cancer treatment for many tumour types. There is increasing evidence that primary tumour excision can hasten metastasis in some patients by triggering cancer dissemination and growth. [10] [11] [12] [13] [14] Circulating tumour cells can be dormant for long periods of time. One study of former, clinically disease-free, breast cancer patients demonstrated that 59% had circulating tumour cells 7-22 yr after mastectomy. 15 These cells live for only a few hours, so they must be continually replenished by a source. Tumours are contained within the chemical and hormonal milieu of the body, and communicate with it through complex cellular signals. Primary tumours secrete both inducers and inhibitors that can influence circulating tumour cells. Once the primary tumour is removed, the balance of inducers to inhibitors can potentially be disrupted, leading to activation of the circulating tumour cells and metastasis. 10 All of this is occurring under the watchful eye of the immune system. It is suspected that cancer cells are not only able to evade the body's defenses, but are also able to communicate with and modulate the immune system. Surgery has long been known to suppress the immune system. This often follows an elevated production of stress hormones and a dramatic inflammatory response. 16 17 Proinflammatory cytokine concentrations and the duration of their elevation have been shown to be correlated with surgical insult, lasting as long as 3-5 days after surgery. 17 Both experimental and clinical studies have shown that surgery inhibits T-cell, B-cell, and NK-cell function for days after a surgical insult. 17 Natural killer cells, in particular, are known to play an important role in tumour development and metastatic spread. 18 In humans, NK-cell activity is correlated with susceptibility to multiple types of cancer. 19 In an elegant study, Melamed and colleagues 20 demonstrated that surgery results in decreased NK-cell activity and increased metastasis, and that blocking the stress and inflammatory responses associated with surgery reverses these effects. In laparotomized rats, surgery significantly decreased NK-cell activity and increased lung tumour retention and lung metastasis after i.v. inoculation with MADB106 cancer cells compared with non-operated, anaesthetized control rats. MADB106 is a mammary adenocarcinoma cell line that metastasizes only to the lungs. Administration of a β-receptor antagonist (nadolol), a prostaglandin synthesis inhibitor (indomethacin), or both dramatically reduced the effects on lung tumour retention, metastasis, and NK-cell activity. The effect of co-administration was greater than the effect of each administered alone. In addition, administration of clinically relevant doses of a β-receptor agonist (metaproteronol), a prostaglandin (PGE 2 ), or both promoted metastasis of tumour cells. The effect of co-administration was additive. Some of the effects of surgery on the stress response and immune function in the perioperative period are likely to be mediated by pain. Pain has been shown to activate the stress response and suppress the immune system in both animals and humans. 3 Medications that reduce pain, decrease the inflammatory response, or both, such as morphine, fentanyl, and non-steroidal inflammatory drugs (NSAIDs), have been shown to decrease the potential for metastasis in rats and humans. [21] [22] [23] [24] Many of the effects of surgery on pain and the stress response can be reduced dramatically by regional anaesthesia. It is important to note that some elements of the stress response are more difficult to block than others. For example, in infants undergoing heart surgery the dose of fentanyl required to produce analgesia (1-5 μg kg −1 ) is less than that required for haemodynamic stability (5-10 μg kg −1 ), which is less than that required to prevent increases in glucose, cortisol, and catecholamine concentrations (25-50 μg kg −1 ). 16 25 Regional anaesthesia, especially with dense block, has the benefit of being able to markedly reduce or eliminate the surgical stimulus. Studies in heart and abdominal surgery patients have shown that the addition of intraoperative epidural analgesia to general anaesthesia results in reduced plasma concentrations of cortisol, β-endorphin, and epinephrine. 26 27 In abdominal surgery patients, intraoperative epidural analgesia was also associated with higher numbers of lymphocytes and T-helper cells, preserved interferon-γ concentrations, and a beneficial effect on the ratio of Th1/Th2 cytokines. 26 Spinal anaesthesia has also been shown to preserve the Th1/Th2 cytokine ratio in rats undergoing laparotomy, which paralleled its ability to decrease liver metastasis. 28 In 2001, Bar-Yosef and colleagues 29 hypothesized that the addition of spinal to general anaesthesia would result in less immunosuppression and reduced lung metastases in rats inoculated with MADB106 cancer cells. Anaesthetized, nonlaparotomized rats were compared with control rats and with laparotomized rats receiving three different anaesthesia regimens: halothane alone, halothane with morphine i.v., and halothane with spinal anaesthesia. No significant difference in the number of lung metastases existed between the subgroups of anaesthesia without surgical intervention. Surgery with halothane anaesthesia increased the number of metastases two-fold compared with control and anaesthesia-only rats. The addition of spinal block to halothane anaesthesia reversed this, whereas morphine i.v. had no significant effect. Both surgery and anaesthesia decreased NK-cell activity. Neither spinal anaesthesia nor systemic morphine had a significant effect on NK activity.
Anaesthetic agents
General anaesthetic agents themselves are thought to suppress the immune system and promote cancer metastasis. 30 Almost all anaesthetic agents have been shown to have a negative impact on various components of the immune system, such as inhibiting cell-mediated immunity or producing an alteration in the balance of pro-inflammatory and anti-inflammatory cytokines. 31 Volatile anaesthetics appear to have a pronounced negative effect on immune function and cancer spread. Administration of halothane and isoflurane results in increased metastatic spread of melanoma, 32 and halothane and nitrous oxide accelerate postoperative growth of lung cancer metastases in mice. 33 Volatile agents can exert their influence on cancer cells via ii36 | Tedore several mechanisms. They have been shown in various studies to increase concentrations of VEGF and MMPs, known stimulators of angiogenesis, and to increase cancer cell migration in vitro. 30 34-37 In addition, volatile agents have been shown to upregulate hypoxia-inducible factors. These transcription factors are thought to mediate the protective effects of volatile agents on ischaemia-reperfusion injury, but have also been shown to be involved in increased tumorigenesis and metastasis by influencing angiogenesis, energy metabolism, cell proliferation, apoptosis, and cell migration. 30 37-39 In contrast to volatile agents, propofol seems to exhibit a beneficial effect in terms of reducing inflammatory cytokines, preserving NK-cell activity, and inhibiting cancer spread. [40] [41] [42] [43] In addition, propofol has been shown to suppress the synthesis and activation of hypoxia-inducible factors. 30 44 Melamed and colleagues 43 compared the effects of propofol, halothane, ketamine, and thiopental on NK-cell activity and metastatic spread of MADB106 tumour cells in rats. All anaesthetics reduced the number of NK cells, and all anaesthetics except propofol decreased NK-cell activity and increased lung metastases and tumour retention. Ketamine had the greatest effect, increasing metastases more than 2.5-fold. This increase was significantly reduced by pretreatment with the β-receptor antagonist nadolol, suggesting that stimulation of β 2 -adrenergic receptors might underlie the inhibitory effects of ketamine on NK-cell activity.
Local anaesthetics
Local anaesthetics themselves seem to be protective against tumour growth and metastasis. They appear to act via several mechanisms, including direct cytotoxicity and induction of apoptosis; inhibition of proliferation, migration, and invasion; and modulation of gene expression via methylation. 45 Local anaesthetics in high concentrations are known to be cytotoxic to neuronal cells 46 ; their toxicity seems to be correlated with lipid solubility and thus with potency. 46 47 Cytotoxicity includes cell death via necrosis or apoptosis. All local anaesthetics cause necrosis, but lidocaine and bupivacaine cause apoptosis in neuroblastoma cells 46 and in breast and thyroid cancer cells. 48 49 Apoptosis is controlled by a group of intracellular cysteine proteases known as caspases. Chang and colleagues 48 demonstrated that treatment of breast cancer cells with clinically relevant concentrations of lidocaine and bupivacaine induced caspases 7, 8, and 9, resulting in apoptosis and decreased cell viability. In addition, local anaesthetic injection into breast xenografts in mice resulted in evidence of apoptosis, including a higher expression of cleaved caspase 7 and increased byproducts of DNA fragmentation. In another study, this group showed that the treatment of thyroid cancer cells with lidocaine and bupivacaine induced apoptosis and that this effect was mediated by the mitogen-activated protein kinase pathway. 49 Local anaesthetics also inhibit cancer cell proliferation, migration, and invasion. Yoon and colleagues 50 demonstrated that tetracaine and lidocaine inhibited the extension of microtubules and their ability to promote tumour cell aggregation and reattachment. Local anaesthetics can also influence proliferation and invasion via their effects on cell signalling pathways. [51] [52] [53] [54] Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor with an important role in epithelial cell proliferation. Mutations of EGFR have been linked to several types of cancer. 51 Epidermal growth factor receptor is activated via phosphorylation by the binding of specific ligands, including epidermal growth factor (EGF 53 showed that lidocaine inhibited EGF stimulation of EGFR tyrosine kinase activity and inhibited both serum-and EGF-induced proliferation of tongue cancer cells. Cell signalling pathways involving the Src tyrosine protein kinase and intercellular adhesion molecule-1 (ICAM-1) are also linked to tumour growth and metastasis. Src has been implicated in epithelial-to-mesenchymal transformation and decreased cell adhesion, resulting in metastasis. ICAM-1 is a cell surface receptor involved in leucocyte adhesion and is known to facilitate tumour growth and spread. Inflammation and TNF-α increase both the activation of Src and the expression of ICAM-1. 54 Piegeler and colleagues 54 demonstrated that amide local anaesthetics decreased TNF-α-induced Src activation and ICAM-1 phosphorylation in human lung cancer cells and inhibited cancer cell migration. These effects were independent of local anaesthetic sodium channel block. Local anaesthetics can also inhibit cancer cell proliferation by effects on the modulation of gene expression via methylation of DNA. Transcriptional silencing of tumour suppressor genes caused by DNA hypermethylation occurs in many cancers. Lidocaine has been shown to demethylate DNA in breast cancer cell lines, 55 and procaine has been shown to demethylate DNA and inhibit tumour growth in breast, hepatoma, and leukaemia cell lines.
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Finally, many types of cancer, including breast, colon, and prostate, express local-anaesthetic-sensitive voltage-activated sodium channels. [59] [60] [61] [62] Baptista-Hon and colleagues 63 demonstrated that ropivacaine inhibits voltage-activated sodium channels in colon cancer cells and decreases cell invasion. Therefore, blockade of sodium channels might have direct inhibitory effects on cancer cells in addition to having beneficial effects in terms of the blockade of noxious stimuli. 64 
Opioids
Opioid medications have long been thought to suppress the immune system. In 1984, Shavit and colleagues 65 demonstrated that endogenous opioid-mediated footshock stress in rats resulted in suppression of NK-cell activity and that this effect was reversed by administration of naltrexone. Since that time, there has been considerable evidence to support the theory of opioid-mediated immune suppression, and additional evidence pointing to opioid-mediated enhancement of tumorigenesis and metastases. Counteracting this is literature suggesting that opioids do not suppress immune function or contribute to cancer spread. Many studies of the effects of opioids on the promotion of cancer growth are in vitro studies or animal studies using i.v. inoculation of tumour cells or xenografts (tumours transplanted into syngeneic specimens). Gupta and colleagues 66 demonstrated that morphine, like VEGF, stimulates endothelial cell proliferation through the mitogen-activated protein kinase/ extracellular signal-regulated kinase signalling pathway, resulting in angiogenesis. Morphine additionally inhibited apoptosis and promoted cell-cycle progression in endothelial cells. Consistent with these in vitro results, morphine administration resulted in angiogenesis and tumour progression in a rat xenograft model. 66 Likewise, Singleton and colleagues 67 found that opioids 69 Breast cancer patients with the MOR A118G polymorphism show decreased breast cancer-specific mortality. 70 The G allele causes decreased receptor transcription and response to opioid receptor binding. Patients with one or more copies of this allele demonstrate reduced analgesia after opioid administration.
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In contrast to the studies discussed above, other studies examining much higher (3.5-to 14-fold) doses of morphine in the setting of surgery in animal models of cancer have not shown tumour-promoting effects. Using an i.v. inoculation rat model, Page and colleagues 22 found that analgesic doses of morphine inhibited the surgery-induced increase in metastasis without affecting metastasis in rats not undergoing surgery. Doornebal and colleagues 71 used a novel preclinical mouse model for metastatic breast cancer to examine whether morphine in the setting of surgery affects tumour growth and metastasis. This model differed from previously used i.v. inoculation and xenograft models in that it mimicked more closely the physiology of true spontaneous metastasis and the interaction between tumour cells and the immune system. 72 They found that morphine did not facilitate angiogenesis, tumour growth, the composition of immune cells within the tumour, or metastasis in mice undergoing mastectomy. 71 The dose of opioids administered may be important not only because of direct opioid-mediated effects, but also because of the effects of opioids on pain and the stress response. Higher doses of opioids might show tumour-suppressive effects because they are more effective than low-dose opioids in terms of blocking pain and the ensuing stress response to surgery. 21 
Non-steroidal anti-inflammatory drugs
Animal and human studies have shown a clear benefit for NSAIDs in the prevention of cancer. 73 74 These drugs inhibit the activity of cyclooxygenase, which plays an important role in the formation of prostaglandins. Concentrations of COX2 are upregulated in various forms of cancer, including breast, lung, prostate, stomach, pancreas, and bladder cancer. 73 One product of COX2 is PGE 2 , which is pro-inflammatory and is associated with cancer progression. 75 Some of the effects of PGE 2 on cancer cells include enhancement of migration and invasion via activation of EGFR 76 and promotion of angiogenesis. 77 78 Apart from primary prevention, NSAIDs appear to reverse the cancer-promoting effects of surgery and opioids. Administration of indomethacin dramatically reduced the increase in lung metastases and tumour retention produced by surgery in rats inoculated with mammary adenocarcinoma. 20 Farooqui and colleagues 23 studied i.v. inoculation of a highly invasive form of breast cancer in mice. Two weeks of morphine treatment stimulated COX2 and PGE 2 production, stimulated angiogenesis, increased metastasis of breast tumours, and decreased survival in mice. Administration of celecoxib reversed these effects. In a retrospective study of 327 breast cancer patients undergoing mastectomy with axillary dissection, ketorolac administration before surgery was associated with a lower rate of cancer recurrence, while the analgesics sufentanil, ketamine, and clonidine showed no such reduction. 79 Regional anaesthesia and analgesia and cancer progression: clinical trials
Systematic reviews
Systematic reviews looking at the association between survival, cancer recurrence, or both and type of anaesthesia have generally found that current evidence is insufficient to draw any concrete conclusions regarding the benefit of regional anaesthesia (Table 1 ). These analyses have included patients undergoing abdominal, prostate, breast, gastroesophageal, laryngeal, ovarian, and cervical cancer surgeries. A Cochrane Review 80 found the quality of the data examined to be low or very low, and the authors were unable to draw any conclusions. A recent large systematic review 81 included 20 studies with more than 54 000 patients. The authors found perioperative regional anaesthesia to be associated with improved overall survival but not reduced cancer recurrence. Another large review 82 compared the effect of epidural anaesthesia (with or without general anaesthesia) with general anaesthesia alone on survival and recurrence in cancer surgery. This systematic review included more than 46 000 patients and found an overall survival benefit in favour of epidural anaesthesia compared with general anaesthesia alone. An even greater benefit was seen in the colorectal subset of patients. No benefit of epidural anaesthesia was found for recurrence-free survival. Pei and colleagues 83 found no overall benefit to combined epidural and general anaesthesia compared with general anaesthesia in terms of postoperative recurrence and metastasis, although there was a benefit in the subgroup of patients with prostate cancer and in those followed for ≤2 yr after surgery [odds ratio=0.66, 95% confidence interval (CI) 0.46-0.95, P=0.027; and OR=0.70, 95% CI 0.51-0.98, P=0.035, respectively]. As described below, most of these systematic reviews are small and retrospective in nature. Many were intended to be hypothesis generating. Large trials with thousands of patients and years of follow-up will be needed to identify true differences between anaesthetic regimens. Several randomized trials comparing regional anaesthesia and analgesia with general anaesthesia are currently recruiting patients undergoing surgery for breast cancer, colorectal cancer, malignant melanoma, and pancreatic cancer (NCT00418457, NCT00684229, NCT01588847, NCT01318161, and NCT01929915). Two of these (NCT00418457 and NCT00684229) are large, multicentre trials.
If benefit is found for regional anaesthesia in terms of cancer recurrence in large, well-conducted clinical trials, it might still be difficult to tease out what part of that benefit is directly attributable to the regional anaesthetic itself and what part is related to avoidance of other perioperative factors associated with cancer progression, such as pain, the stress response, volatile anaesthetics, and opioids.
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Breast cancer
One of the first studies to examine the question of whether anaesthesia can affect outcome in breast cancer patients was a retrospective review by Exadaktylos and colleagues. 84 This study included 129 patients undergoing mastectomy with axillary dissection, 50 of whom received paravertebral block and general anaesthesia followed by paravertebral infusion for 48 h, and 79 of whom received general anaesthesia alone followed by morphine patient-controlled analgesia. There were no significant differences between groups in terms of patient charateristics, surgical details, tumour presentation, or prognostic factors. The authors found a significant difference favouring paravertebral anaesthesia and analgesia, with a recurrence and metastasisfree survival rate of 94% (95% CI 87-100%) vs 82% (95% CI 74-91%) at 24 months and 94% (95% CI 87-100%) vs 77% (95% CI 68-87%) at 36 months after surgery. In order to provide a more adequate answer to the question of whether regional anaesthesia and analgesia can impact breast cancer recurrence, a large, multicentre international trial is being conducted in patients with Stage 1-3 breast cancer undergoing mastectomy with or without axillary dissection (NCT00418457). 104 One thousand one hundred patients are to be enrolled during 5 yr and will be randomized to a regional anaesthetic technique (thoracic epidural or paravertebral block) with propofol sedation and postoperative regional infusion or to general anaesthesia with sevoflurane and postoperative morphine patient-controlled analgesia. The primary end point will be cancer recurrence. Although we will not have definitive results from trial NCT00418457 for many years, results from in vitro studies performed on tissue and serum samples from patients enrolled in that multicentre trial have produced interesting findings. Regional anaesthesia compared with general anaesthesia resulted in a greater percentage decrease in postoperative compared with preoperative concentrations of the pro-inflammatory cytokine IL-1β, an increase in the concentrations of anti-inflammatory IL-10, and a significant attenuation of MMPs involved in tumour migration and metastasis. 35 Serum from the regional anaesthesia group reduced proliferation (but not migration) of an aggressive cancer cell line 105 and increased apoptosis to a greater extent than serum from the general anaesthesia group. 106 When incubated with serum from subjects receiving regional anaesthesia, donor NK cells demonstrated greater cytotoxicity than when exposed to serum from subjects in the general anaesthesia group. 106 Excised breast cancer specimens from the regional anaesthesic group demonstrated increased infiltration of NK and T-helper cells when compared with the general anaesthesia group. 107 This same group of investigators also showed that paravertebral anaesthesia led to a significantly smaller increase than general anaesthesia in VEGF-C, which is known to promote angiogenesis and to be overexpressed in breast cancer. 34 Another study, however, showed no difference between paravertebral block with sevoflurane general anaesthesia and general anaesthesia alone in terms of VEGF and PGE 2 production, although the paravertebral group had lower glucose, cortisol, and C-reactive protein concentrations. 108 Both groups received diclofenac before surgery, which could have affected the results.
Prostate cancer
Prostate cancer is problematic in survival outcome studies because patients live for many years after diagnosis. It is estimated that cancer-specific survival in organ-confined prostate cancer is >95% at 10 yr. 109 Patients with disease that has spread outside of the prostate are at increased risk of rapid progression. Reported cancer-specific survival rates and biochemical recurrence (BCR) at 10 and 15 yr are 63-90 and 25-79, and 40 and 60%, respectively. 110 111 Therefore, when trying to discern a difference in survival between treatment groups it is most practical to enrol patients with advanced disease. Studies examining survival outcomes in prostate cancer often use BCR as an end point. Biochemical recurrence is often defined as either an increase of prostate-specific antigen from its postoperative nadir, or at a specific value such as >0.2 ng ml −1 . 85 87 Biochemical recurrence is an imperfect end point for studies because it does not translate into cancer-specific survival. 112 There have not been any randomized controlled trials examining the effect of regional anaesthesia on survival in prostate cancer. Most studies are retrospective. Two studies have shown an advantage of general combined with epidural anaesthesia and analgesia compared with general anaesthesia alone. 85 86 Biki and colleagues 85 going radical prostatectomy, ∼50% of whom had invasive disease. They found that general and epidural anaesthesia and analgesia resulted in better clinical progression-free survival but found no differences between groups in terms of BCR-free survival, cancer-specific survival, or overall survival. One should be cautious in interpreting the lack of difference between groups, however, in light of the fact that the sample size was small, and as such, the study had sufficient power to detect only large differences. The general anaesthesia group also received ketorolac every 8 h, which might have confounded the results. Cyclooxygenase 2 is overexpressed in prostate cancer cells, 113 and COX2
inhibitors have been shown to induce apoptosis in prostate cancer cell lines. 114 115 There are four studies in the literature showing no benefit for regional anaesthesia and analgesia in prostate cancer surgery. 87 88-90 One retrospective study by Wuethrich and colleagues 87 showed no difference in any end point, including BCR-free, local and distant recurrence-free, cancer-specific, and overall survival in patients with invasive prostate cancer undergoing radical prostatectomy with combined general and epidural anaesthesia and analgesia or general anaesthesia alone. This study was small, and the patients in the general anaesthesia group received ketorolac analgesia, which might have affected the results. The study by Forget and colleagues 88 was large, with 1111 patients, and examined patients with localized disease undergoing radical prostatectomy. The goal of this study was to evaluate the impact of epidural anaesthesia and analgesia, along with a host of other analgesics, including sufentanil, ketorolac, clonidine, and ketamine, on BCR-free surival. The authors found a significantly reduced BCR-free survival rate associated with i.v. sufentanil, hazard ratio 7.78 (95% CI 5.79-9.78), but no significant effect from epidural analgesia or any of the other studied analgesics. Unfortunately, this study had a short follow-up time (mean 38 months), a significant number of patients receiving adjuvant treatments, and overlapping anaesthesia and analgesia regimens. Another study finding no difference in BCR in patients with localized disease was small and examined patients in a secondary analysis of a previous randomized controlled trial evaluating pain control, blood loss, and transfusion requirements. 89 A large retrospective study by Roiss and colleagues included 4772 patients undergoing radical prostatectomy with either general anaesthesia alone or general anaesthesia combined with single-injection spinal anaesthesia. They found no difference between groups in terms of overall survival, BCR-free survival, and overall survival. There were significant differences between groups with respect to prostate-specific antigen concentrations, tumour grade, and histology, although these differences were accounted for with propensity-score matching.
Colorectal cancer
Two studies evaluating the effect of regional anaesthesia on colorectal cancer recurrence after resection are secondary analyses of previously conducted randomized controlled trials that compared general and epidural anaesthesia and analgesia with general anaesthesia. 92 observed no difference in overall survival or disease-free survival when comparing epidural, spinal, and patient-controlled analgesia in a total of 457 patients.
Other cancers
The association between regional anaesthesia and cancer recurrence has been studied retrospectively in other cancer types, including melanoma, cervical cancer, and laryngeal cancer. A single study has shown a benefit for regional anaesthesia and analgesia in 271 patients undergoing surgery for laryngeal and hypopharyngeal cancer. 98 When compared with general anaesthesia alone, combined general and epidural anaesthesia with postoperative epidural analgesia resulted in significantly improved cancer-free survival and improved overall survival. A protective role for regional anaesthesia has been seen in metastatic melanoma. Schlagenhauff 
Conclusions
During and after surgery, there are multiple factors at play in determining whether tumour cells released during primary tumour resection result in cancer metastasis and progression. Regional anaesthesia, analgesia, or both is unlikely to be the primary determinant in perioperative cancer progression, but one small part of the equation for certain cancers. Its use, however, may avoid exposure to other factors resulting in cancer progression, such as stress hormone release, uncontrolled or poorly controlled pain, and exposure to volatile anaesthetics and opioids. Multimodal perioperative pain regimens using regional anaesthesia in conjunction with other known protective measures, such as NSAIDs, may also be beneficial. Only well-conducted, large, randomized controlled trials, some of which are underway, will answer the question of whether regional anaesthesia can truly reduce cancer recurrence and increase survival.
